A small pharma client with limited budget had several clinical compounds in Phase I and II, and one globally approved commercial product. They required robust processes for the evaluation of single and aggregate data to strengthen stakeholder review and documentation management associated with serious adverse events (SAEs).
Join Qinecsa at J.P. Morgan Healthcare Conference 2024
Qinecsa is on a mission to drive positive change in the pharmacovigilance industry. As we enter a new year with exciting plans to continue advancing pharmacovigilance solutions, we look forward to engaging with industry leaders and investors at the forefront of...
